Elkfork Partners’s Akero Therapeutics AKRO Stock Holding History

Elkfork Partners’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$11K	Hold	484	–	–	﹤0.01%	1048
2019 Q2	$9K	Buy	+484	New	+$9.17K	﹤0.01%	1045

Other funds holding AKRO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Elkfork Partners's AKRO Position: Q3 2019 in Review

Elkfork Partners held its Akero Therapeutics (AKRO) position steady in Q3 2019 at 484 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #1048.

Elkfork Partners first reported a position in AKRO in Q2 2019 and has held it in 2 quarters since. 54 funds tracked by Wall St. Rank hold AKRO as of Q3 2019.

Elkfork Partners held 484 shares of Akero Therapeutics worth $11K as of Q3 2019.
Elkfork Partners left its Akero Therapeutics share count unchanged in Q3 2019.
Akero Therapeutics made up ﹤0.01% of Elkfork Partners's portfolio in Q3 2019, its #1048 holding.
Elkfork Partners first reported a position in Akero Therapeutics in Q2 2019 and has held it in 2 quarters since.
54 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.